Financhill
Back

Plus Therapeutics Quote, Financials, Valuation and Earnings

Plus Therapeutics Price Quote

$0.43
-0.01 (-2.27%)
(Updated: January 26, 2023 at 8:10 PM ET)

Plus Therapeutics Key Stats

Buy
55
Plus Therapeutics (PSTV) is a Buy

Day range:
$0.42 - $0.45
52-week range:
$0.29 - $1.20
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
1.52
P/B ratio:
1.3%

Volume:
135.6K
Avg. volume:
402.7K
1-year change:
-49.17%
Market cap:
$14.8M
Revenue:
$0
EPS:
$-0.89

How Much Does Plus Therapeutics Make?

Data Unavailable

Is Plus Therapeutics Growing As A Company?

Data Unavailable

Plus Therapeutics Stock Price Performance

What Is Plus Therapeutics 52-Week High & Low?

Plus Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Plus Therapeutics?

  • How Much Debt Does Plus Therapeutics Have?
    Total long term debt quarterly is $0
  • How Much Cash Does Plus Therapeutics Have?
    Cash and short term investments quarterly total is $20.3M
  • What Is Plus Therapeutics’s Book Value Per Share?
    Book value per share is 0.35

Is Plus Therapeutics Cash Flow Positive?

  • What Is PSTV Cash Flow From Operations?
    Cash flow from operations (TTM) is -$13.4M
  • What Is Plus Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $13.1M
  • What Is Plus Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$746K

Plus Therapeutics Return On Invested Capital

Data Unavailable

Plus Therapeutics Earnings Date & Stock Price

Plus Therapeutics Competitors

Plus Therapeutics Dividend Yield

Data Unavailable

Plus Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -26.32%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 1
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 3.58
Upside from Last Price: 714.39%

Major Shareholders

  • How many PSTV shares are owned by institutional investors?
    5.7M PSTV shares are owned by institutional investors
  • How many PSTV shares are owned by insiders?
    1.2M PSTV shares are owned by insiders